This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Entasis Therapeutics Holdings Past Earnings Performance
Past criteria checks 0/6
Key information
-7.8%
Earnings growth rate
117.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -86.5% |
| Return on equity | -310.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2022 |
Recent past performance updates
Recent updates
Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?
Dec 16
Entasis Therapeutics: AstraZeneca Spin-Out Developing Targeted Antibacterial Products
Nov 17Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?
Aug 19Entasis Therapeutics shares rise after lining up ETX0462 poster presentation
Jun 18What Kind Of Shareholders Own Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)?
Feb 17
Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?
Dec 01Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Entasis Therapeutics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 22 | 0 | -52 | 17 | 39 |
| 31 Dec 21 | 0 | -47 | 15 | 37 |
| 30 Sep 21 | 0 | -46 | 14 | 38 |
| 30 Jun 21 | 0 | -45 | 13 | 39 |
| 31 Mar 21 | 0 | -46 | 13 | 39 |
| 31 Dec 20 | 0 | -50 | 13 | 41 |
| 30 Sep 20 | 0 | -54 | 14 | 42 |
| 30 Jun 20 | 7 | -46 | 14 | 40 |
| 31 Mar 20 | 7 | -46 | 14 | 41 |
| 31 Dec 19 | 7 | -44 | 14 | 40 |
| 30 Sep 19 | 7 | -38 | 12 | 36 |
| 30 Jun 19 | 0 | -52 | 11 | 37 |
| 31 Mar 19 | 5 | -44 | 10 | 35 |
| 31 Dec 18 | 5 | -42 | 10 | 33 |
| 30 Sep 18 | 5 | -43 | 10 | 34 |
| 30 Jun 18 | 5 | -34 | 9 | 33 |
| 31 Mar 18 | 0 | -35 | 8 | 30 |
| 31 Dec 17 | 0 | -30 | 6 | 26 |
Quality Earnings: ETTX is currently unprofitable.
Growing Profit Margin: ETTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ETTX is unprofitable, and losses have increased over the past 5 years at a rate of 7.8% per year.
Accelerating Growth: Unable to compare ETTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ETTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).
Return on Equity
High ROE: ETTX has a negative Return on Equity (-310.58%), as it is currently unprofitable.